Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation

International Journal of Oncology

Volumn 40, Issue 2, 2012, Pages 402-408

  Kim, Eun Jin ^a   Lee, So Yong ^a   Woo, Mi Kyung ^b   Choi, Soo Im ^a,c   Kim, Tae Rim ^a   Kim, Min Jung ^a   Kim, Kug Chan ^a   Cho, Eun Wie ^b   Kim, In Gyu ^a,c  

^a Korea Atomic Energy Research Institute   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c University of Science and Technology (UST)   (South Korea)

Author keywords

Fibulin 3; Invasion; Lung cancer; Methylation; MMP 7; Tumour suppressor

Indexed keywords

FIBULIN 3; GELATINASE A; GLYCOPROTEIN; MATRILYSIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DNA MICROARRAY; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; PYROSEQUENCING;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; DNA METHYLATION; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION;

EID: 84862920643     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1191     Document Type: Article

References (36)

1. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 3415-3428, 2002.
2. Jones PA and Baylin SB: The epigenomics of cancer. Cell 128: 638-692, 2007.
3. Kim TY, Zhong S, Fields CR, Kim JH and Robertson KD: Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 66: 7490-7501, 2006. (Pubitemid 44289203)
4. Alaminos M, Davalos V and Ropero S: EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of candidate tumor suppressor in glioma and neuroblastoma. Cancer Res 65: 2565-2571, 2005. (Pubitemid 40490052)
5. Shames DS, Minna JD and Gazdar AF: DNA methylation in health, disease, and cancer. Curr Mol Med 7: 85-102, 2007. (Pubitemid 46322281)
6. Yue W, Dacic S, Sun Q, et al: Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 13: 4336-4344, 2007. (Pubitemid 47219697)
7. Zhang Y, Wang R, Song H, et al: Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 303: 21-28, 2011.
8. Wang R, Zhang YW and Chen LB: Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma. Lung Cancer 69: 239-244, 2010.
9. Timpl R, Sasaki T, Kostka G and Ghu MI: Fibulins: versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 4: 479-489, 2003. (Pubitemid 36648593)
10. De Vega S, Iwamoto T and Yamada Y: Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 66: 1890-1902. 2009.
11. Schiemann WP, Blobe GC, Kalume DE, Pandey A and Lodish HF: Context-specific effect of fibulin-5(DANCE/EVEC) on proliferation, motility, and invasion: fibulin-5 is induced by TGF-β and affects protein kinase cascades. J Biol Chem 277: 27367-27377, 2002. (Pubitemid 34951757)
12. Albig AR and Schimann WP: Fibulin-5 antagonizes vascular endothelial growth factor signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol 23: 367-379, 2004. (Pubitemid 38850384)
13. Albig AR, Neil JR and Schimann WP: Fibulin-3 and -5 antagonize tumor angiogenesis in vivo. Cancer Res 66: 2621-2629, 2006.
14. Yue W, Sun Q, Landreneau R, Wu C, Siegfried JM, Yu J and Zhang L: Fibulin-5 suppress lung cancer invasion by inhibiting matrix metalloproteinase-7 expression. Cancer Res 69: 6339-6346, 2009.
15. Ghallagher WM, Currid CA and Whelan LC: Fibulins and cancer: friend or foe? Trends Mol Med 11: 336-340, 2005. (Pubitemid 40984716)
16. Tost J and Gut IG: DNA methylation analysis by pyrosequencing. Nat Protoc 2: 2265-2275, 2007. (Pubitemid 351575045)
17. Kim EJ, Lee SY, Kim TR, Choi SI, Cho EW, Kim KC and Kim IG: TSPYL5 is involved in cell growth and resistance to radiation in A549 cells via the regulation of p21waf1/cip1 and PTEN/Akt pathway. Biochem Biophys Res Commun 392: 448-453, 2010.
18. Das AK, Sato M and Story MD: Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 66: 9601-9608, 2006. (Pubitemid 44623659)
19. Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierré A and Atassi G: Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res 6: 297-304, 2000. (Pubitemid 30065005)
20. Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431, 2002.
21. Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG, Zheng S and Huang J: Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 31: 1376-1380, 2010.
22. Shen X, Artinyan A, Jackson D, Thomas RM, Lowy AM and Kim J: Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways. Pancreas 39: 81-87, 2010.
23. Zhang Z, Song T, Jin Y, Pan J, Zhang L, Wang L and Li P: Epidermal growth factor receptor regulates MT1-MMP and MMP-2 synthesis in SiHa cells via both PI3-K/AKT and MAPK/ERK pathways. Int J Gynecol Cancer 19: 998-1003, 2009.
24. Wu HH, Cheng YW, Chang JT, Wu TC, Liu WS, Chen CY and Lee H: Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kappaB activation. Oncogene 29: 4330-4340, 2010.
25. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67, 2010.
26. Stone EM, Lotery AJ, Munier FL, et al: A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet 22: 199-202, 1999. (Pubitemid 29264819)
27. Loeys BL, Coucke PJ, De Paepe A, et al: Fibulin-5 mutations: mechanisms of impaired elastic fiber formation in recessive cutis laxa. Hum Mol Genet 15: 3379-3386, 2006. (Pubitemid 44811590)
28. Bardin A, Moll F, Margueron R, et al: Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology 146: 760-768, 2005. (Pubitemid 40129832)
29. Argraves WS, Greene LM, Cooley MA and Gallagher WM: Fibulins: physiological and disease perspectives. EMBO Rep 4: 1127-1131, 2003. (Pubitemid 38088406)
30. Sicot FX, Tsuda T, Markova D, et al: Fibulin-2 is dispensable for mouse development and elastic fiber formation. Mol Cell Biol 28: 1061-1067, 2008. (Pubitemid 351160062)
31. Qing J, Maher VM, Tran H, Argraves WS, Dunstan RW and McCormick JJ: Suppression of anchorage-independent growth and matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines. Oncogene 15: 2159-2168, 1997. (Pubitemid 27493905)
32. Hu B, Thirtamara-Rajamani KK, Sim H and Viapiano MS: Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 7: 1756-1770, 2009.
33. Seeliger H, Camaj P, Ischenko I, et al: EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 7: 189-198, 2009.
34. Sadr-Nabavi A, Ramser J, Volkmann J, et al: Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 124: 1727-1735, 2009.
35. Hwang CF, Chien CY, Huang SC, et al: Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol 222: 367-379, 2010.
36. Camaj P, Seeliger H, Ischenko I, et al: EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem 390: 1293-1302, 2009.